February 25th 2021
Paris, February 25, 2021 – 7:00 pm CET
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announced the publication of the Company’s 2020 Universal Registration Document for the year ended December 31, 2020.
The document, filed with the French stock-market authority (Autorité des Marchés Financiers) on February 24, 2021, is available to the public free of charge upon request, as per current legal regulations; and on the Company’s website under the section Investors / Documentation / Regulated information, as well as on that of the AMF (www.amf-france.org).
It notably includes the2020 annual financial report, the report on corporate governance, the required information in relation to the share repurchase program, as well as the auditors’ reports and information on the fees paid to the statutory auditors in 2020.